DGAP-News: Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients
(firmenpresse) - DGAP-News: Proteo Biotech AG / Key word(s): Study/Research Update
Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary
bypass patients
16.08.2011 / 10:53
---------------------------------------------------------------------
Proteo, Inc. / Proteo Biotech AG:
EMPIRE-Study recruits first coronary bypass patients
Irvine, CA - Kiel, 16th August, 2011 Proteo, Inc. (OTCQB: PTEO; Freiverkehr
Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG
announced today: The first two patients have been recruited into the
EMPIRE-Study which will investigate the efficacy of the naturally occurring
human protease inhibitor Elafin in preventing complications of coronary
bypass surgery. 'We are optimistic that Elafin will reduce cardiac muscle
injury and post-operative inflammatory responses in patients receiving a
bypass', commented Professor Oliver Wiedow, chairman of the supervisory
board of Proteo Biotech AG, a company specializing in the research and
development of new pharmaceuticals with emphasis on anti-inflammatory
substances.
The study is being performed under the supervision of the cardiologist Dr.
Peter Henriksen at NHS Lothian's Edinburgh Heart Centre in association with
The University of Edinburgh, one of the leading European universities in
the area of cardiovascular research, and the Edinburgh Clinical Trials
Unit. The aim of the study is to investigate the efficacy and safety of
intraoperatively administered Elafin in coronary bypass surgery.
Inflammation of cardiac muscle and the resulting muscle injury after a
bypass operation remain a frequent and unresolved problem.
EMPIRE (Elafin Myocardial Protection from Ischaemia Reperfusion Injury) is
a placebo-controlled, double-blinded, monocentric Phase-II study with 80
patients. The study will be funded by the Medical Research Council (MRC)
and Chest Heart&Stroke Scotland (CHSS) with funding in excess of 500,000
GBP.
Further information on the clinical development program for Elafin:
Proteo's pharmaceutical Elafin is a copy of a naturally occurring human
anti-inflammatory substance. It is a natural antagonist of the tissue
destroying enzymes (proteases) that participate in the inflammatory
mechanism of many diseases. Elafin's ability to block the enzymes that
cause these undesirable effects makes it a promising drug for the treatment
of e.g. inflammatory lung diseases and severe reperfusion injury. The
excellent tolerability of intravenously administered recombinant Elafin has
already been demonstrated convincingly in a Phase I clinical trial. The
outcome of a Phase II clinical trial on the treatment of postoperative
inflammatory reactions in esophagus carcinoma show that intravenously
administered Elafin has a very clear positive effect on the period of
recovery: 63 percent of the Elafin treated patients required only one day
of intensive care. All patients in the placebo group needed several days of
postoperative intensive medical care. In addition, Proteo's licensing and
development partner, Minapharm Pharmaceuticals SAE, has initiated a Phase
II clinical trial on the use of Elafin for kidney transplantation patients.
This trial is concerned with the prevention of acute organ rejection and
chronic graft injury (allograft nephropathy).
About Proteo:
The company researches, develops and markets compounds for biological and
medical research as well as for use as pharmaceuticals. The main focus is
on anti-inflammatory drugs, in particular on the human protease inhibitor
Elafin. Proteo intends to out-license selected indications and to establish
international strategic alliances in order to open up new fields of
application and for marketing (www.proteo.de).
Forward-looking statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact:
Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Germany
Email: info(at)proteo.de
Phone +49(0)431 8888462
Fax: +49(0)431 8888463
End of Corporate News
---------------------------------------------------------------------
16.08.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
135825 16.08.2011
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.08.2011 - 10:53 Uhr
Sprache: Deutsch
News-ID 46824
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 344 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteo Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
